Comparative Pharmacology
Head-to-head clinical analysis: COSOPT versus COSOPT PF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COSOPT versus COSOPT PF.
COSOPT vs COSOPT PF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cosopt is a combination of dorzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-adrenergic receptor antagonist. Dorzolamide inhibits carbonic anhydrase II in the ciliary processes, decreasing aqueous humor secretion. Timolol reduces aqueous humor production by blocking beta-2 adrenergic receptors in the ciliary epithelium.
Fixed combination of a carbonic anhydrase inhibitor (dorzolamide) and a beta-adrenergic antagonist (timolol). Dorzolamide inhibits carbonic anhydrase II in the ciliary processes, reducing aqueous humor secretion. Timolol antagonizes beta-2 adrenergic receptors in the ciliary epithelium, decreasing aqueous humor production.
One drop in the affected eye(s) twice daily.
One drop in the affected eye(s) twice daily, approximately 12 hours apart. The combination product contains dorzolamide 2% and timolol 0.5%.
None Documented
None Documented
Dorzolamide: terminal half-life ~4 months due to carbonic anhydrase binding in RBCs (slow dissociation); timolol: 4 hours, prolonged in renal impairment
Dorzolamide: ~4 months (due to RBC binding); Timolol: 3-4 hours for parent drug, but pharmacodynamic effect may persist longer.
Dorzolamide: renal excretion of unchanged drug and N-desethyl metabolite accounts for approximately 70% of the dose, with ~20% as unchanged drug. Timolol: ~20% renal excretion unchanged, remainder as metabolites in urine
Dorzolamide: 70-80% renal elimination as unchanged drug and N-desethyl metabolite; ~20% fecal. Timolol: 20% renal unchanged, rest metabolized in liver with metabolites excreted renally.
Category C
Category C
Ophthalmic glaucoma agent
Ophthalmic glaucoma agent